Yahoo · Sep 21, 2026
Are Options Traders Betting on a Big Move in Journey Medical Stock?
Investors need to pay close attention to DERM stock based on the movements in the options market lately.
DE
NASDAQ · DERM
Journey Medical Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
$6.61
Down-$0.11 (-1.64%)
Updated Oct 5, 2026, 8:19 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 178.63M
- P/E ratio
- -20.66
- Dividend yield
- 0.00%
- 52-week range
- $4.31 – $9.56
- Volume
- 126.17K
- Avg. volume
- 167.08K
Price performance · DERM
DERM price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
DERM closed at $6.61 after 19 trading sessions, down 17.06% for the selected period.
- Last close
- $6.61
- Period change
- -17.06%
- Period low
- $6.14
- Period high
- $7.97
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $6.83 | $6.88 | $6.47 | $6.61 | 126.17K |
| Oct 1, 2026 | $6.83 | $6.83 | $6.68 | $6.72 | 103.83K |
| Sep 30, 2026 | $6.52 | $6.89 | $6.43 | $6.84 | 167.24K |
| Sep 29, 2026 | $6.42 | $6.555 | $6.30 | $6.49 | 92.71K |
| Sep 28, 2026 | $6.11 | $6.495 | $6.08 | $6.43 | 149.86K |
| Sep 25, 2026 | $6.38 | $6.43 | $6.09 | $6.14 | 216.31K |
| Sep 24, 2026 | $6.43 | $6.64 | $6.20 | $6.32 | 364.63K |
| Sep 23, 2026 | $7.23 | $7.25 | $6.445 | $6.50 | 342.38K |
| Sep 22, 2026 | $7.04 | $7.40 | $6.975 | $7.25 | 227.37K |
| Sep 21, 2026 | $7.44 | $7.525 | $6.86 | $6.99 | 282.69K |
| Sep 18, 2026 | $7.31 | $7.61 | $7.285 | $7.31 | 259.78K |
| Sep 17, 2026 | $7.53 | $7.66 | $7.33 | $7.36 | 116.25K |
| Sep 16, 2026 | $7.39 | $7.62 | $7.255 | $7.29 | 224.69K |
| Sep 15, 2026 | $7.39 | $7.40 | $7.13 | $7.36 | 149.09K |
| Sep 14, 2026 | $7.16 | $7.43 | $7.16 | $7.38 | 99.56K |
| Sep 11, 2026 | $7.21 | $7.405 | $7.06 | $7.23 | 168K |
| Sep 10, 2026 | $7.38 | $7.70 | $7.05 | $7.09 | 265.19K |
| Sep 9, 2026 | $7.90 | $7.90 | $7.42 | $7.45 | 117.9K |
| Sep 8, 2026 | $7.84 | $7.975 | $7.67 | $7.97 | 134.12K |
Latest DERM news
The latest Smart Investors Daily articles mentioning DERM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DERM research
Overview
Company profile and research snapshot.
Company profile
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | B. Riley Securities | Buy | — |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 25, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2025 | Lake Street | Buy | — |
| Jul 30, 2025 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 19, 2026
Journey Medical: A Small Pharma With A Large Growth Opportunity
Journey Medical (DERM) is rated Buy, driven by Emrosiâs rapid prescription growth and expanding payer coverage.
Yahoo · Aug 19, 2026
Journey Medical (DERM) Q2 2026 Earnings Call Transcript
Emrosi prescriptions hit 14,000 in July as payer coverage expands and margins improve.
Yahoo · Aug 19, 2026
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Nirav Jhaveri, Chief Financial Officer Nirav Jhaveri, Chief Financial Officer Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Com
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
